ArticleJournal of Crohn's & colitis2026
Plasma lipopolysaccharide-binding protein (LBP), a proxy for intestinal permeability, relates to clinicopathological and immunological disease activity in inflammatory bowel disease patients at diagnosis and during disease course.
Article in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
aimsIntestinal barrier healing is the treatment goal in ulcerative colitis (UC) and Crohn's disease (CD). Despite this, systematic analyses of the relationship between intestinal permeability and clinicopathological and immunological disease activity at diagnosis and during follow-up are lacking. Therefore, we assessed this relationship using plasma lipopolysaccharide-binding protein (LBP)-an indirect biomarker of systemic exposure to bacterial endotoxins-as a proxy for intestinal permeability, in a uniquely well-characterized pediatric inflammatory bowel disease (IBD) cohort.
methodsLBP was measured in 1083 longitudinal plasma samples of newly diagnosed pediatric UC (n = 61), CD (n = 115) (PIBD-SETQuality and TISKids prospective cohorts; median follow-up 628 days), and controls (IBD-negative, n = 33; healthy, n = 28). Its relationship with clinicopathological parameters and plasma immune proteomics was examined.
resultsPlasma LBP was elevated and associated with clinicopathological disease activity in therapy-naive CD and UC. In UC, but not CD, LBP related to disease extent, and strongly and independently correlated to endoscopic and histological disease activity, providing additional explanatory value beyond routinely used blood-based biomarkers and inflammatory mediators (including CRP and IL-6). LBP correlated with disease-specific immune profiles linked to severe disease (IL-17/neutrophil/IFN-γ-related profile in UC; IFN-γ-related profile in CD). LBP decreased after induction therapy with corticosteroids in UC, and after exclusive enteral nutrition or anti-TNF (but not corticosteroids) in CD. LBP remained associated with clinicopathological disease activity during follow-up, particularly in UC.
conclusionsPlasma LBP relates to clinicopathological and immunological disease activity in IBD-especially UC-at diagnosis and during follow-up, and provides complementary information to routinely used blood-based biomarkers, arguing this simple, inexpensive parameter should be (re)considered for monitoring mucosal inflammation in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.